Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20698647 | 0.89 | GLA (0.37) | TACR1KCNH2GLACYP2A6GRM5 | |
| SCHEMBL20980657 | 0.81 | GRM5 (0.38) | TACR1KCNH2GLAGRM5MRGPRX4 | |
| SCHEMBL12736230 | 0.81 | TACR1 (0.46) | TACR1ALDH1A1 | |
| SCHEMBL20980896 | 0.78 | TACR1 (0.44) | TACR1XDHMRGPRX4 | |
| SCHEMBL16955860 | 0.77 | GLA (0.36) | KCNH2GLAXDHALDH1A1CYP2A6 | |
| SCHEMBL800275 | 0.76 | GLA (0.54) | TACR1GLAGRM5MRGPRX4 | |
| SCHEMBL19764850 | 0.75 | CD274 (0.38) | GRM5ENPP2 | |
| SCHEMBL799863 | 0.74 | CYP2A6 (0.52) | TACR1KCNH2ALDH1A1CYP2A6 | |
| SCHEMBL23373746 | 0.74 | CYP2A6 (0.34) | KCNH2GLACYP2A6GRM5MRGPRX4 | |
| SCHEMBL22477339 | 0.74 | CYP2A6 (0.39) | KCNH2XDHALDH1A1CYP2A6GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | TACR1 329/4885KCNH2 3640/4885GLA 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.